SAB Biotherapeutics Q2 FY26 net loss widens to $22.5 million; R&D expenses more than doubled to $16.2 million - SABS News | RalliesSAB Biotherapeutics Q2 FY26 net loss widens to $22.5 million; R&D expenses more than doubled to $16.2 million
S
SABS• Quarterly results
- SAB BIO posted a Q2 net loss of $22.5 million, widening from a loss of $10.1 million a year earlier.
- R&D expenses climbed to $16.2 million from $7 million, on higher clinical trial costs and related headcount.
- G&A expenses rose to $7.2 million from $2.7 million, driven by higher headcount costs including stock-based compensation.
Cash position and trial update
- Cash, cash equivalents and investment securities totaled $208 million at June 30, 2026, providing operational runway through 2028.
- More than 60 sites are recruiting for the registrational SAFEGUARD trial of SAB-142, with enrollment targeted for completion in Q4 2026.
DHT
•
